Determination of the ED95 of intranasal sufentanil combined with intranasal dexmedetomidine for moderate sedation during endoscopic ultrasonography

Table 4 The posterior probability for each intranasal sufentanil

Patients	Allocated SUF dose, μg/kg	Clinical response(Success 1, Failure 0)	SUF dose, μg/kg
			0	0.1	0.2	0.3	0.4	0.5
			Prior estimated probability for each dose (%)
			50	75	90	95	98	99
			Posterior probability for each dose (%)
1-3	0.3	1,1,1	62.5	80.0	91.6	95.7	98.3	99.1
4-6	0.3	1,1,1	65.4	82.0	92.5	96.2	98.5	99.2
7-9	0.3	1,1,1	67.8	83.6	93.3	96.6	98.6	99.3
10-12	0.3	1,1,1	70.0	84.9	93.9	96.9	98.8	99.4
13-15	0.2	1,1,1	73.6	87.0	94.8	97.4	99.0	99.5
16-18	0.2	1,1,1	76.4	88.7	95.5	97.8	99.1	99.6
19-21	0.2	1,0,0	47.4	71.7	88.2	94.0	97.6	98.8
22-24	0.3	1,1,1	49.3	73.1	88.8	94.3	97.7	98.9
25-27	0.3	1,1,1	51.1	74.3	89.4	94.6	97.8	98.9
28-30	0.3	1,1,1	52.8	75.4	89.9	94.9	98.0	99.0

In bold is the estimated ED₉₅ after the inclusion of each cohort. SUF: Sufentanil.